Murine MET Expressing NIH3T3 Cell Lines

NIH 3T3 cell lines with various hepatocyte growth factor receptor or MET mutations using murine constructs.

MET or hepatocyte growth factor receptor (HGFR) is a protein involved in tyrosine kinase activity. MET is a single pass tyrosine kinase receptor that is essential for embryonic development, organogenesis and wound healing.

From the laboratory of Laura S. Schmidt, PhD, National Cancer Institute/NIH.

Catalog Number Product Size AVAILABILITY Price Qty
ENH023-FP
Murine MET (Wild-Type) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH024-FP
Murine MET (V1110I) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH025-FP
Murine MET (H1112Y) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH026-FP
Murine MET (H1112L) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH027-FP
Murine MET (H1124D) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH028-FP
Murine MET (M1149T) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH029-FP
Murine MET (V1206L) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH030-FP
Murine MET (L1213V) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH031-FP
Murine MET (V1238I) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH032-FP
Murine MET (Y1248H) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH033-FP
Murine MET (Y1248D) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00
ENH034-FP
Murine MET (M1268T) Expressing NIH3T3 Cell Line, 1 Vial
1 vial 3-5 weeks
Price: $599.00

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.

Specifications
Product Type: Cell Line
Name: Named based on human MET mutation
Cell Type: Wild-type murine MET and murine MET mutations (based on human nomenclature) V1206L, V1110I, H1112Y, H1112L, H1124D, M1149T, L1213V, V1238I, Y1248H, Y1248D, M1268T in NIH3T3 cells
Organism: Mouse
Source: Embryo/established with stable transfection of mutant murine MET constructs into NIH3T3 cells with G418 selection
Morphology: Fibroblast
Biosafety Level: 1
Subculturing: 80% confluent
Growth Conditions: DMEM, 10%FBS, 1% glutamine, 500 ug/ml G418 (Geneticin)
Cryopreservation: DMEM, 25%FBS, 10% DMSO (v/v), 500 ug/ml G418
Storage: Liquid nitrogen
Shipped: Dry Ice
Provider
From the laboratory of Laura S. Schmidt, PhD, National Cancer Institute/NIH.
Comments

NOTE: These cell lines have not been sequence verified since 1997 and it is recommended that purchasing investigators should do so before beginning experiments.

  • NIH3T3 cell line (ATCC#CRL-1658) was the original line used for transfection, which produces only 2 sactter units/ml HGF/SF, significantly lower than most NIH 3T3 sublines.
  • The wild-type Met expression vector contains murine Met cDNA in the pMB1 expression vector (Park, M., Dean, M., Kaul, K., Braun, M. J., Gonda, M. A. & Vande Woude, G. F. (1987) Proc. Natl. Acad. Sci. USA 84, 6379–6383.) Mutations in wild type MET were introduced by site-directe mutagenesis. (ref 1 below).
  • Nucleotides are numbered according to the scheme in GenBank Accession number J02958 with nucleotide (-194) in the cDNA (Park et al., 1987) given the number 1. Amino acids were numbered as in the reference by Park et al. (1987).
References
  1. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11445-50.
  2. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999 Apr 8;18(14):2343-50.
 
Loading...
Loading...